Výsledky vyhledávání

DT-PACE/ESHAP chemotherapy regimens as salvage therapy for multiple myeloma prior to autologous stem cell transplantation

Autor: Simon Cheesman, Nicholas Counsell, X. Papanikolaou, Jackie Horder, Jonathan Sive, Louise Ainley, Neil Rabin, Fiona Newrick, Ashutosh D. Wechalekar, Kwee Yong, Atul Mehta, Charalampia Kyriakou, Rakesh Popat, Lydia Lee, Selina J Chavda

Publikováno v: British journal of haematologyReferences. 192(3)

Routine use of novel agents to treat newly diagnosed and relapsed multiple myeloma (MM) produces high response rates and improved survival. However, 15–20% of patients have suboptimal responses and their management remains challenging.1 Traditional

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5030163a76d52ace2251aef6bfad1206
https://pubmed.ncbi.nlm.nih.gov/33236352

Zobrazit plný text záznamu

Reduced-intensity conditioning allogeneic transplantation after salvage treatment with DT-PACE in myeloma patients relapsing early after autologous transplant

Autor: Lynn Ryan, Kathy Holder, Lynda Baker, Kate Randall, Emmanouil Nikolousis, Julie Suhr, Richard Lovell, Bhuvan Kishore, Evgenia Xenou, Alexandros Kanellopoulos, Maria Kaparou, Shankara Paneesha

Publikováno v: European journal of haematology. 99(4)

Objective In this retrospective single center study we have looked into the transplant outcomes(overall survival OS, progression free survival PFS,GvHD) and the role of chimerism, DLI and pre-transplant characteristics in patients who had a suboptima

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bbc9d80b961b98171e16fcac43ffd7ea
https://pubmed.ncbi.nlm.nih.gov/28632322

Zobrazit plný text záznamu

Total therapy-based treatment for multiple myeloma--a single center experience

Autor: Pia Raanani, Ron Ram, Anat Gafter-Gvili, Moshe Yeshurun, Ofer Shpilberg, Hila Magen-Nativ

Publikováno v: Annals of hematology. 89(1)

Incorporation of novel biological agents has become the cornerstone of treatment in multiple myeloma. For the last 4 years we have adopted the more intensified approach, previously published as total therapy 3 by the Arkansas group and used it with l

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9607e341418553c5c6f2d1cb56d448d9
https://pubmed.ncbi.nlm.nih.gov/19504094

Zobrazit plný text záznamu

Survival and outcome of blastoid variant myeloma following treatment with the novel thalidomide containing regime DT-PACE

Autor: Bronwen E. Shaw, Gareth J. Morgan, Faith E. Davies, Ping Wu, Sharon Dines, Mark Ethell, Matthew W Jenner, Muralikrishnan Srikanth, Radovan Saso, Michael Potter

Publikováno v: European journal of haematology. 81(6)

Blastoid morphology is a rare presenting feature of myeloma which is frequently seen in patients with extramedullary myeloma and is associated with poor clinical outcome. Cell cycle active agents can be effective as treatment for aggressive myeloma a

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f82809da162915fa5b1fe0aaa1281032
https://pubmed.ncbi.nlm.nih.gov/18691254

Zobrazit plný text záznamu

Akademický článek

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Melphalan 200mg/m2 (MEL 200) and MEL 140/DT-PACE Are Equally Effective in Multiple Myeloma (MM), While the Latter Is Less Toxic

Autor: Maureen Reiner, Bart Barlogie, Guido Tricot, Maurizio Zangari, Frits van Rhee

Publikováno v: Blood. 106:839-839

MEL 200 is now generally accepted to represent the best preparative regimen for autotransplantation in MM patients. We have previously reported that DT-PACE is very effective in inducing rapid responses even in high risk myeloma (JCO 2003, 31: 73–8

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::437fe0feab96927842654166fb344952
https://doi.org/10.1182/blood.v106.11.839.839

Zobrazit plný text záznamu

Phase I Trial of Bortezomib (V) in Combination with 'DT-PACE': Toxicity, Stem Cell Collection and Engraftment in Newly Diagnosed Multiple Myeloma (MM) Patients (Pts)

Autor: Kathleen Ruehle, S. Hefner, Barry Meisenberg, Sandra Westphal, Aaron P. Rapoport, Ashraf Badros, Olga Goloubeva

Publikováno v: Blood. 106:2747-2747

Several studies have established the safety and efficacy of V in various regimens before stem cell mobilization and transplant (SCT). The primary objective of our study was to determine the MTD of V (3 dose levels: 0.7, 1.0, 1.3 mg/m2 days 1, 4, and

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::133866e678a553f27b9c1541b9062c44
https://doi.org/10.1182/blood.v106.11.2747.2747

Zobrazit plný text záznamu

Mobilization of Stem Cells with DT-PACE Plus Pegfilgrastim vs. DT-PACE Plus Filgrastim in Previously Treated MM Patients

Autor: Michele Cottler-Fox, Maureen Reiner, Maurizio Zangari, Guido Tricot, Bart Barlogie, Frits van Rhee, Michael J. Burns

Publikováno v: Blood. 106:1972-1972

Mobilization with chemotherapy (CT) plus hematopoietic growth factors (HGFs) is superior to mobilization with HGFs only. For stem cell mobilization after chemotherapy HGFs are typically given once or twice a day for approximately 14 days. The aim of

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::a265d7b22677d54a3e0e9b5289c27e27
https://doi.org/10.1182/blood.v106.11.1972.1972

Zobrazit plný text záznamu

Total Therapy 3 (TT 3) for Newly Diagnosed Myeloma, Incorporating Velcade into Remission Induction with DT PACE: Early Results Regarding Efficacy, PBSC Mobilization and Toxicities

Autor: Athanasios Fassas, Guido Tricot, Teresa Milner, Bart Barlogie, Klaus Hollmig, Maurizio Zangari, Julie Stover, Lisa Jackson

Publikováno v: Blood. 104:538-538

TT 3 represents a further development of the Total Therapy concept after completion of accrual to TT 2 with 668 patients. Based on the high salvage potential of the Velcade + Thal + Dex (VTD) regimen for endstage MM, VTD had been added to PACE (4 day

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::9c21a56accea6280c80c490a9cf58de6
https://doi.org/10.1182/blood.v104.11.538.538

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání